Cwm LLC Makes New $89,000 Investment in GeneDx Holdings Corp. (NASDAQ:WGS)

Cwm LLC acquired a new position in shares of GeneDx Holdings Corp. (NASDAQ:WGS) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,091 shares of the company’s stock, valued at approximately $89,000.

Several other institutional investors have also recently bought and sold shares of WGS. Oracle Investment Management Inc. raised its holdings in GeneDx by 531.7% during the first quarter. Oracle Investment Management Inc. now owns 1,126,607 shares of the company’s stock worth $10,286,000 after buying an additional 948,253 shares during the last quarter. Driehaus Capital Management LLC bought a new stake in shares of GeneDx in the 2nd quarter worth $11,335,000. Assenagon Asset Management S.A. bought a new stake in shares of GeneDx in the 2nd quarter worth $9,575,000. Divisadero Street Capital Management LP bought a new stake in shares of GeneDx in the 2nd quarter worth $5,886,000. Finally, Gagnon Securities LLC grew its stake in shares of GeneDx by 59.3% in the 1st quarter. Gagnon Securities LLC now owns 556,305 shares of the company’s stock worth $5,079,000 after acquiring an additional 207,027 shares in the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

Insiders Place Their Bets

In other GeneDx news, major shareholder Opko Health, Inc. sold 12,994 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $29.35, for a total transaction of $381,373.90. Following the completion of the transaction, the insider now owns 2,971,570 shares in the company, valued at $87,215,579.50. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, major shareholder Opko Health, Inc. sold 12,994 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $29.35, for a total value of $381,373.90. Following the sale, the insider now directly owns 2,971,570 shares of the company’s stock, valued at approximately $87,215,579.50. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Kevin Feeley sold 895 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $33.33, for a total transaction of $29,830.35. Following the completion of the sale, the chief financial officer now directly owns 39,910 shares in the company, valued at approximately $1,330,200.30. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 408,668 shares of company stock worth $13,544,988 over the last quarter. 28.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. BTIG Research upped their target price on shares of GeneDx from $35.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. TD Cowen upped their target price on shares of GeneDx from $46.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Craig Hallum upped their target price on shares of GeneDx from $46.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday. Wells Fargo & Company initiated coverage on shares of GeneDx in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $34.00 target price for the company. Finally, The Goldman Sachs Group increased their price target on shares of GeneDx from $32.00 to $54.00 and gave the company a “neutral” rating in a research report on Wednesday, October 16th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, GeneDx currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.67.

GeneDx Price Performance

WGS opened at $58.82 on Friday. The firm has a market cap of $1.54 billion, a P/E ratio of -11.36 and a beta of 2.32. The firm has a 50-day moving average of $43.27 and a 200 day moving average of $31.08. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.22 and a current ratio of 2.38. GeneDx Holdings Corp. has a fifty-two week low of $1.16 and a fifty-two week high of $61.96.

GeneDx (NASDAQ:WGS) last issued its earnings results on Tuesday, July 30th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.15. The firm had revenue of $70.51 million during the quarter, compared to analyst estimates of $58.90 million. GeneDx had a negative net margin of 48.21% and a negative return on equity of 22.71%. On average, research analysts expect that GeneDx Holdings Corp. will post -0.75 EPS for the current year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.